Lupin Pharma Canada debuts Propranolol LA, filling gap left by Inderal LA
Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited, has officially launched its Propranolol LA capsules in Canada, signaling a milestone in affordable healthcare solutions. The newly introduced Propranolol LA comes in four different dosages: 60 mg, 80 mg, 120 mg, and 160 mg. This medication serves as a generic alternative to the recently discontinued Inderal LA, providing both patients and healthcare providers with a vital treatment option.
Propranolol LA: A Boon for Canadian Healthcare Accessibility
Designed to meet the specific needs of Canadian patients, Propranolol LA reaffirms Lupin Pharma’s commitment to improving healthcare access and affordability across Canada. As the only extended-release formulation of Propranolol available to Canadian patients, Propranolol LA fills a significant gap left by the withdrawal of Inderal LA from the market.
Extended-Release Formulation Enhances Treatment and Quality of Life
Propranolol LA’s extended-release formula contributes not only to sustained symptom relief but also to increased patient adherence and an improved overall quality of life. By launching Propranolol LA, Lupin Pharma Canada is advancing its mission to meet unmet patient needs effectively.
Lupin Pharma’s Ongoing Commitment to Healthcare Solutions
Dr. Sofia Mumtaz, President – Legal, Canada, Australia, and Japan, Lupin, expressed enthusiasm about the new launch. “We are delighted to announce the introduction of Propranolol LA capsules for Canadian patients. We’ve worked diligently to expand our portfolio to include Propranolol LA, thereby ensuring patients have access to essential medicines. This launch signifies our enduring commitment to providing healthcare solutions that truly make a difference,” she said.
By unveiling Propranolol LA, Lupin Pharma Canada Ltd. not only enhances treatment options but also exemplifies its dedication to accessible and affordable healthcare in Canada. The new Propranolol LA capsules are poised to bring much-needed relief and improved quality of life to Canadian patients.